Clinical Trial Update: SU5416 in Treating Patients With Malignant Mesothelioma [Phase 2]

View source ↗

Summary

The clinical trial update reports the completion of a Phase 2 study of SU5416 in patients with malignant mesothelioma, sponsored by the National Cancer Institut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• SU5416 (semaxanib) (semaxanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Malignant Mesothelioma | Phase 2 | Status: COMPLETED